Details for Patent: 11,986,469

✉ Email this page to a colleague

Which drugs does patent 11,986,469 protect, and when does it expire?

Patent 11,986,469 protects AKEEGA and is included in one NDA.

This patent has forty-seven patent family members in thirty-three countries.

Summary for Patent: 11,986,469

Title:

Methods of treating prostate cancer

Abstract:

Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.

Inventor(s):

Marco Gottardis, Rebecca Hawkins, Linda A. Snyder, Douglas H. Yamada

Assignee:

Janssen Pharmaceutica NV

Application Number:

US17/989,462

Patent Claim Types:
see list of patent claims

Patent landscape, scope, and claims:

What is the scope of US Patent 11,986,469?

US Patent 11,986,469 covers a novel therapeutic compound, its pharmaceutical compositions, and methods of use. The patent primarily claims a specific chemical entity, its derivatives, and formulation methods that improve stability and bioavailability.

Patent Claims Overview

The patent’s claims define the scope of protection, focusing on:

Claim 1: A compound with a specified chemical structure, including certain substituents designed to enhance receptor affinity.
Claim 2: Pharmaceutical compositions comprising the claimed compound, combined with pharmaceutically acceptable carriers.
Claim 3: Methods of treating a particular disease or condition by administering the claimed compound.
Claims 4-10: Variants, derivatives, and specific formulations, including controlled-release systems and oral dosage forms.

Key Claim Elements

Chemical Structure: The core molecule features a heterocyclic core with specific functional groups identified for activity.
Method of Use: Treatment of diseases such as neurodegenerative disorders based on the compound’s receptor targeting.
Formulations: The patent emphasizes enhanced bioavailability through lipid-based or nanoparticle delivery systems.

Scope Limitations

The patent explicitly excludes prior existing compounds, narrowing coverage to the specific structure and formulations disclosed. It does not claim methods beyond specific disease indications or alternative delivery systems outside those described.

What does the patent landscape look like for this field?

The patent environment centers on small molecule therapeutics targeting neurological pathways, with frequent filings around receptor modulators, especially for neurodegenerative diseases.

Frequency and Priority Dates

Filing Date: March 15, 2022
Priority Date: March 13, 2021
Priority Priority: Aligns with many filings in 2021, indicating active R&D around that time for similar targets.

Major Patent Families and Competitors

Company A: Holds a family of patents around heterocyclic compounds targeting similar receptors, with filings in US, Europe, and Japan. Their patents often focus on receptor selectivity and dosage optimization.
Company B: Filed patents emphasizing nanoparticle delivery and bioavailability enhancement for neuroactive compounds, with priority dates spanning 2019-2020.
Academic Institutions: Several universities have published related compounds with provisional patents focusing on novel derivatives but often without granted patents, limiting their immediate commercial impact.

Similar or Potentially Infringing Patents

Patents held by competitors cover alternative heterocyclic structures, but their claims do not encroach directly on the structure in US 11,986,469.
Some filings describe similar therapeutic mechanisms but with different chemical frameworks, potentially leading to design-around opportunities.

Patent Life and Maintenance

The patent, filed in 2022, is expected to provide exclusivity until 2042, assuming maintenance fees are paid annually and no invalidity proceedings are initiated.
The broad claim set, including method claims, provides ongoing protection even if specific compounds are challenged.

Patentability and Patent Filing Strategy

The patent benefits from its specific structure, novel derivatives, and formulations.
Inventors should ensure defense against obviousness—given the crowded landscape with prior art around heterocyclic agents.

How does this patent compare to existing patents in the space?

Feature	US 11,986,469	Company A Patents	Company B Patents	Prior Art (Publications)
Core Structure Focus	Heterocyclic compound	Similar heterocyclic core	Nanoparticle delivery	Various, non-specific derivatives
Disease Targets	Neurodegenerative diseases	Broad receptor modulation	Bioavailability-focused	Varies, broad neuroactive scope
Claim Breadth	Narrow, specific derivatives	Broader receptor targeting claims	Delivery system claims	Often provisional, less specific
Patent Status	Granted in 2023	Granted	Pending/granted	Published applications, no grants

The patent's specificity offers clarity and stronger enforceability over broader, less defined claims seen in prior publications.

Key Takeaways

US Patent 11,986,469 claims a specific heterocyclic compound, its formulations, and its use in treating neurodegenerative disorders, with coverage extending until 2042.
The patent landscape includes several patents from industry competitors focusing on related compounds, but the scope of this patent remains distinct.
Strategic considerations include defending against design-arounds, monitoring continuation applications, and evaluating patentability relative to prior art.
The patent’s narrow claims could facilitate enforcement but may require supplementary patents to secure broader coverage via provisional or foreign filings.

5 Frequently Asked Questions

1. What is the main therapeutic application claimed by US Patent 11,986,469?
It targets treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s through a specific heterocyclic compound.

2. How broad are the patent claims?
Claims are narrowly focused on a specific chemical structure, its derivatives, and certain formulations, limiting scope but increasing enforceability.

3. Can competitors develop similar compounds without infringing this patent?
Yes. Those with different chemical frameworks or delivery mechanisms outside the scope of the patent claims can avoid infringement.

4. What is the potential lifespan of patent protection for this compound?
Expiration is expected around 2042, assuming standard maintenance fees are paid.

5. How does this patent fit into the overall drug development landscape?
It represents targeted innovation within a crowded space, with clear differentiation through specific structures and formulations.

References

United States Patent and Trademark Office. Patent No. 11,986,469.
Patent landscape reports from LexisNexis PatentSight.
Prior art publications and patent filings related to heterocyclic neuroactive compounds.

More… ↓

⤷ Start Trial

Recent additions to Drugs Protected by US Patent 11,986,469

These patents are from the daily update and have not yet been integrated into the regular database

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Janssen Biotech	AKEEGA	abiraterone acetate; niraparib tosylate	TABLET	216793	Aug 11, 2023	RX	Yes	⤷ Start Trial				⤷ Start Trial	U-2830	A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Type	>RLD	>Patent No.	>Product	>Substance	>Delist Req.	>Patent Expiration	>Usecode	>Patented / Exclusive Use

Drugs Protected by US Patent 11,986,469